The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233.
Timur Mitin
No relevant relationships to disclose
Asha George
No relevant relationships to disclose
Anthony L. Zietman
No relevant relationships to disclose
Donald S. Kaufman
No relevant relationships to disclose
Robert G. Uzzo
No relevant relationships to disclose
Robert Dreicer
No relevant relationships to disclose
Niall M. Heney
No relevant relationships to disclose
H. James Wallace
No relevant relationships to disclose
Luis Souhami
No relevant relationships to disclose
M. Chris Dobelbower
No relevant relationships to disclose
Howard Mark Sandler
Consultant or Advisory Role - Bayer; Medivation; Sanofi
William U. Shipley
No relevant relationships to disclose